Goldman Sachs Group Inc. Sells 501,725 Shares of Sanofi $SNY

Goldman Sachs Group Inc. cut its holdings in shares of Sanofi (NASDAQ:SNY) by 20.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,977,603 shares of the company’s stock after selling 501,725 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.08% of Sanofi worth $95,835,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Flagship Harbor Advisors LLC bought a new stake in shares of Sanofi in the 4th quarter valued at about $25,000. Measured Wealth Private Client Group LLC bought a new stake in shares of Sanofi in the 3rd quarter valued at about $29,000. Palisade Asset Management LLC bought a new stake in shares of Sanofi in the 3rd quarter valued at about $30,000. Annis Gardner Whiting Capital Advisors LLC raised its holdings in shares of Sanofi by 544.4% in the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 696 shares of the company’s stock valued at $34,000 after purchasing an additional 588 shares during the period. Finally, Larson Financial Group LLC raised its holdings in shares of Sanofi by 48.9% in the 4th quarter. Larson Financial Group LLC now owns 810 shares of the company’s stock valued at $39,000 after purchasing an additional 266 shares during the period. 14.03% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on SNY shares. Morgan Stanley set a $52.00 target price on shares of Sanofi in a report on Friday, May 1st. Weiss Ratings raised shares of Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. Argus raised shares of Sanofi to a “strong-buy” rating in a report on Monday, April 27th. Wall Street Zen cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. Finally, Bank of America cut shares of Sanofi from a “buy” rating to a “neutral” rating in a report on Thursday, February 12th. Two investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $51.00.

Sanofi Stock Performance

Shares of NASDAQ:SNY opened at $44.73 on Wednesday. The company’s 50 day moving average price is $45.36 and its two-hundred day moving average price is $46.64. Sanofi has a 12-month low of $42.28 and a 12-month high of $52.68. The firm has a market cap of $108.44 billion, a PE ratio of 12.49, a PEG ratio of 1.08 and a beta of 0.34. The company has a quick ratio of 0.22, a current ratio of 1.01 and a debt-to-equity ratio of 0.17.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which was paid on Wednesday, June 3rd. Stockholders of record on Monday, May 4th were paid a dividend of $2.4225 per share. The ex-dividend date of this dividend was Monday, May 4th. This is an increase from Sanofi’s previous annual dividend of $2.04. This represents a dividend yield of 559.0%. Sanofi’s payout ratio is 49.16%.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.